A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs Pyrotinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jun 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jul 2016.
- 12 Dec 2015 Status changed from active, no longer recruiting to completed, as per results presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium